Monod Bio Announces Appointment of Timothy I. Still as Executive Chairman

• Accomplished executive brings more than 35 years of experience in medical technology as Monod Bio accelerates commercialization efforts

SEATTLE, Oct. 1, 2025 /PRNewswire/ -- Monod Bio, a leader in computational protein design, today announced the strengthening of its leadership team with the appointment of Timothy I. Still as Executive Chairman of the Board. Monod Bio uses AI-powered de novo protein design to create novel protein binders that serve as antibody replacements and biosensors for in vitro diagnostics (IVD) and research use only (RUO) applications.

"We are thrilled to have Tim join our Board as Executive Chairman," said Daniel Silva Manzano, CEO and Founder of Monod Bio. "We are confident that his deep expertise in executing highly focused commercial strategies will be invaluable as we enter an aggressive growth phase and cement our position at the forefront of AI-powered protein design in diagnostics and life science tools."

As a 35+ year industry veteran, Mr. Still brings a wealth of experience in medical diagnostics and life science tools. Throughout his career, Tim has been directly responsible for building the commercial viability at numerous companies - many of which have been successfully acquired. With a career spanning numerous CEO and Board appointments, his background brings financial, commercial and business development leadership and expertise to Monod Bio.

"Monod Bio's de novo protein design platform has the potential to fundamentally change diagnostics and research markets," said Mr. Still. "The company has a truly innovative vision and a highly skilled and dedicated team. I look forward to working with the board and the management team to help guide the company's strategic direction and deliver long-term value to our stakeholders."

About Monod Bio
Monod Bio is a Seattle-based biotechnology company and a spinout from the David Baker Lab at the University of Washington's Institute for Protein Design. The company uses AI-powered de novo protein design to create novel protein binders and biosensors for invitro diagnostics and research use only applications. Monod Bio's proprietary platform enables the generation of novel proteins, including its NovoBody™ binders, to address unmet needs. Through its "Monod Inside" business model, Monod Bio partners with leading RUO and IVD organizations to bring next-generation products to market. For more information, visit monod.bio.

SOURCE Monod Bio